Stock Scorecard



Stock Summary for EyePoint Pharmaceuticals Inc (EYPT) - $9.40 as of 11/20/2024 4:02:47 PM EST

Total Score

10 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for EYPT

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for EYPT

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for EYPT

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for EYPT

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for EYPT (38 out of 90)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0

Latest News for for EYPT

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 ) - EyePoint Pharmaceuticals ( NASDAQ:EYPT ) 11/18/2024 12:00:00 PM
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals ( EYPT ) : Can the Stock Really Move This High? 11/13/2024 2:55:00 PM
EyePoint Pharmaceuticals ( EYPT ) Reports Q3 Loss, Lags Revenue Estimates 11/7/2024 1:35:00 PM
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - EyePoint Pharmaceuticals ( NASDAQ:EYPT ) 11/4/2024 12:00:00 PM
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering 10/30/2024 1:47:00 AM
EyePoint Pharmaceuticals ( EYPT ) Soars 27.6%: Is Further Upside Left in the Stock? 10/29/2024 8:49:00 AM
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock - EyePoint Pharmaceuticals ( NASDAQ:EYPT ) 10/28/2024 9:14:00 PM
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock 10/28/2024 9:14:00 PM
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss - EyePoint Pharmaceuticals ( NASDAQ:EYPT ) 10/28/2024 4:16:00 PM
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - PROCEPT BioRobotics ( NASDAQ:PRCT ) 10/28/2024 2:14:00 PM

Financial Details for EYPT

Company Overview

Ticker EYPT
Company Name EyePoint Pharmaceuticals Inc
Country USA
Description EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company is headquartered in Watertown, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name LABORATORY ANALYTICAL INSTRUMENTS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 9.40
Price 4 Years Ago 6.58
Last Day Price Updated 11/20/2024 4:02:47 PM EST
Last Day Volume 1,405,014
Average Daily Volume 974,803
52-Week High 30.99
52-Week Low 5.87
Last Price to 52 Week Low 60.14%

Valuation Measures

Trailing PE N/A
Industry PE 27.34
Sector PE 40.32
5-Year Average PE -5.34
Free Cash Flow Ratio 2.53
Industry Free Cash Flow Ratio 102.40
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 5.50
Total Cash Per Share 3.72
Book Value Per Share Most Recent Quarter 4.09
Price to Book Ratio 2.87
Industry Price to Book Ratio 800.29
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 13.75
Industry Price to Sales Ratio Twelve Trailing Months 3.81
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 8
Analyst Strong Buy Ratings 4

Share Statistics

Total Shares Outstanding 68,251,000
Market Capitalization 641,559,400
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 1.26%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 30.77%
Reported EPS 12 Trailing Months -1.99
Reported EPS Past Year -1.67
Reported EPS Prior Year -1.83
Net Income Twelve Trailing Months -103,570,000
Net Income Past Year -70,795,000
Net Income Prior Year -102,254,000
Quarterly Revenue Growth YOY -30.80%
5-Year Revenue Growth 37.20%
Operating Margin Twelve Trailing Months -3.11

Balance Sheet

Total Cash Most Recent Quarter 253,800,000
Total Cash Past Year 280,200,000
Total Cash Prior Year 331,000,000
Net Cash Position Most Recent Quarter 223,800,000
Net Cash Position Past Year 250,200,000
Long Term Debt Past Year 30,000,000
Long Term Debt Prior Year 30,000,000
Total Debt Most Recent Quarter 30,000,000
Equity to Debt Ratio Past Year 0.88
Equity to Debt Ratio Most Recent Quarter 0.88
Total Stockholder Equity Past Year 228,305,000
Total Stockholder Equity Prior Year 266,323,000
Total Stockholder Equity Most Recent Quarter 218,734,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -118,037,000
Free Cash Flow Per Share Twelve Trailing Months -1.73
Free Cash Flow Past Year -1,608,000
Free Cash Flow Prior Year -67,155,000

Options

Put/Call Ratio 0.09
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.22
MACD Signal 0.53
20-Day Bollinger Lower Band 7.05
20-Day Bollinger Middle Band 9.29
20-Day Bollinger Upper Band 11.53
Beta 1.52
RSI 38.12
50-Day SMA 15.25
150-Day SMA 10.39
200-Day SMA 10.58

System

Modified 11/21/2024 12:29:30 AM EST